(ARGX) and Zai Lab Limited (ZLAB) announced that China’s National Medical Products Administration, NMPA, approved the supplemental ...
Just a few months into a new launch in chronic inflammatory demyelinating polyneuropathy (CIDP), agrenx’ Vyvgart is already making headway in the rare disease space, just one of the long-term growt | ...
Netherlands biotech Argenx has a second FDA approval for its FcRn inhibitor Vyvgart Hytrulo, adding a new indication in chronic inflammatory demyelinating polyneuropathy (CIDP) for a drug that it ...
Argenx (NASDAQ:ARGX) has received FDA approval for Vyvgart Hytrulo for the treatment of adults with chronic inflammatory demyelinating polyneuropathy, or CIDP. The Dutch biotech company said the ...
The firm sees upside potential for the shares driven by Vyvgart sales and key trial outcomes and Phase 3 starts expected over the next 12 months. Steady quarter-over-quarter growth in the ...
ARGEN is a patented light scattering instrument that addresses key research and development issues in the biopharmaceutical industry by providing real-time stability monitoring, manufacturing ...
Zai Lab (NASDAQ:ZLAB) and argenx (NASDAQ:ARGX) traded higher in the premarket Wednesday after China added myasthenia gravis therapy Vyvgart (efgartigimod alfa) to the 2023 National Reimbursement ...
If you're not a LEGO Insider, you can sign up for free. LEGO insiders who purchase the set anytime from November 1–7 will receive a LEGO Marvel Cerebro set as a free gift, which includes the ...